Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?
- PMID: 33345706
- PMCID: PMC8215085
- DOI: 10.1177/1073858420981866
Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?
Abstract
Both sepsis and treatment of cancer with chemotherapy are known to cause neurologic dysfunction. The primary defects seen in both groups of patients are neuropathy and encephalopathy; the underlying mechanisms are poorly understood. Analysis of preclinical models of these disparate conditions reveal similar defects in ion channel function contributing to peripheral neuropathy. The defects in ion channel function extend to the central nervous system where lower motoneurons are affected. In motoneurons the defect involves ion channels responsible for subthreshold currents that convert steady depolarization into repetitive firing. The inability to correctly translate depolarization into steady, repetitive firing has profound effects on motor function, and could be an important contributor to weakness and fatigue experienced by both groups of patients. The possibility that disruption of function, either instead of, or in addition to neurodegeneration, may underlie weakness and fatigue leads to a novel approach to therapy. Activation of serotonin (5HT) receptors in a rat model of sepsis restores the normal balance of subthreshold currents and normal motoneuron firing. If an imbalance of subthreshold currents also occurs in other central nervous system neurons, it could contribute to encephalopathy. We hypothesize that pharmacologically restoring the proper balance of subthreshold currents might provide effective therapy for both neuropathy and encephalopathy in patients recovering from sepsis or treatment with chemotherapy.
Keywords: ICUAW; action potential; chemotherapy; excitability; motoneuron; motor neuron; neuropathy; oxaliplatin; sepsis; subthreshold current.
Conflict of interest statement
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures






Similar articles
-
Reduced motor neuron excitability is an important contributor to weakness in a rat model of sepsis.Exp Neurol. 2016 Aug;282:1-8. doi: 10.1016/j.expneurol.2016.04.020. Epub 2016 Apr 24. Exp Neurol. 2016. PMID: 27118372 Free PMC article.
-
Increasing motor neuron excitability to treat weakness in sepsis.Ann Neurol. 2017 Dec;82(6):961-971. doi: 10.1002/ana.25105. Epub 2017 Dec 7. Ann Neurol. 2017. PMID: 29171917 Free PMC article.
-
Reduced motoneuron excitability in a rat model of sepsis.J Neurophysiol. 2013 Apr;109(7):1775-81. doi: 10.1152/jn.00936.2012. Epub 2013 Jan 9. J Neurophysiol. 2013. PMID: 23303860 Free PMC article.
-
Modulation of the intrinsic properties of motoneurons by serotonin.Curr Pharm Des. 2013;19(24):4371-84. doi: 10.2174/13816128113199990341. Curr Pharm Des. 2013. PMID: 23360270 Review.
-
Central Role of Subthreshold Currents in Myotonia.Ann Neurol. 2020 Feb;87(2):175-183. doi: 10.1002/ana.25646. Epub 2019 Nov 27. Ann Neurol. 2020. PMID: 31725924 Free PMC article. Review.
Cited by
-
Neural circuit mechanisms of sensorimotor disability in cancer treatment.Proc Natl Acad Sci U S A. 2021 Dec 21;118(51):e2100428118. doi: 10.1073/pnas.2100428118. Proc Natl Acad Sci U S A. 2021. PMID: 34911753 Free PMC article.
-
Delayed Onset Muscle Soreness and Critical Neural Microdamage-Derived Neuroinflammation.Biomolecules. 2022 Aug 31;12(9):1207. doi: 10.3390/biom12091207. Biomolecules. 2022. PMID: 36139045 Free PMC article. Review.
References
-
- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, and others. 2004. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350:2343–51. - PubMed
-
- André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, and others. 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical